Jesus Berdeja, MD
There has been no shortage of data in the setting of newly diagnosed multiple myeloma, explained Jesus Berdeja, MD. Research has ranged from exploration of more intensive regimens in transplant-ineligible patients to that of quadruplet regimens in transplant-eligible patients.
State of the Science Summit™ on Hematologic Malignancies, Berdeja, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discussed emerging standards of care in transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma.
OncLive®: What are some emerging developments in the newly diagnosed setting of multiple myeloma?
a: When a patient is diagnosed with multiple myeloma, we have to decide whether or not they are a transplant candidate. There are some differences in opinion, but ultimately, we all have a way to decide who is transplant-eligible and who is transplant-ineligible.
... to read the full story